Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria

Nanomedicine

Volumn 9, Issue 5, 2014, Pages 649-666

  Borhade, Vivek ^a   Pathak, Sulabha ^b   Sharma, Shobhona ^b   Patravale, Vandana ^a  

^a INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

4 day suppressive test; atovaquone; crystalline state; malaria; nanosuspension; oral absorption; particle size; solubility and dissolution

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CAPRYOL 90; NANOCRYSTAL; PROGUANIL; SOLUTOL HS 15; STABILIZING AGENT; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; EMULSION; NANOCAPSULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; MALARIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NANOSUSPENSION; NONHUMAN; PARASITEMIA; PARTICLE SIZE; PHYSICAL CHEMISTRY; PILOT STUDY; PLASMODIUM BERGHEI INFECTION; PRECIPITATION; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DIFFUSION; EMULSION; METABOLIC CLEARANCE RATE; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; ANIMALS; ANTIMALARIALS; ATOVAQUONE; DIFFUSION; DRUG COMPOUNDING; EMULSIONS; MALARIA; MALE; METABOLIC CLEARANCE RATE; MICE; NANOCAPSULES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84901017184     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.13.61     Document Type: Article

References (39)

1. Bangchang KN, Karbwang J. Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fundam. Clin. Pharmacol. 23(4), 387-409 (2009
2. Lewison G, Srivastava D. Malaria research, 1980-2004, and the burden of disease. Acta Trop. 106(2), 96-103 (2008
3. Bathurst I, Hentschel C. Medicines for malaria venture: Sustaining antimalarial drug development. Trends Parasitol. 22(7), 302-307 (2006
4. Gelb MH. Drug discovery for malaria: A very challenging and timely endeavor. Curr. Opin. Chem. Biol. 11(4), 440-445 (2007
5. Magalhaes NSS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev. 62(4-5), 560-575 (2010
6. Baggish AL, Hill DR. Antiparasitic agent atovaquone. Antimicrob. Agents Chemother. 46(5), 1163-1173 (2002
7. Singh BN. A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, Dose/ solubility ratio, and partition coefficient for orally active drugs administered as immediate-release formulations. Drug Dev. Res. 65, 55-75 (2005
8. Nicolaides E, Galia E, Dressman JB, Reppas C. Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 16(12), 1876-1882 (1999
9. Malarone̊ tablets, product information. GlaxoSmithKline Inc., CA, USA (2009
10. Musset L, Bouchaud O, Matheron S, Massias L, Bras JL. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome B codon 268 mutations. Microb. Infect. 8(11), 2599-2604 (2006
11. Mepron̊ suspension, product information.GlaxoSmithKline Inc, CA, USA (2009
12. Shubar HM. Effect of Surfactants on the Therapeutic Efficacy of Atovaquone Nanosuspensions Against Acute and Reactivated Murine Toxoplasmosis. Dissertation submitted to Free University of Berlin, Germany (2009
13. Sugano K, Kataoka M, Mathews CC, Yamashita S. Prediction of food effect by bile micelles on oral drug absorption considering free fraction in intestinal fluid. Eur. J. Pharm. Sci. 40, 118-124 (2010
14. Sek L, Boyd BJ, Charman WN, Porter CJH. Examination of the impact of a range of pluronic surfactants on the in vitro solubilization behavior and oral bioavailability of lipidic formulations. J. Pharm. Pharmacol. 58, 809-820 (2006
15. Sordet F, Amjaud Y, Fessi H, Derouin F. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite 5(3), 223-229 (1998
16. Cauchetier E, Paul M, Rivollet D et al. Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int. J. Parasitol. 30(6), 777-783 (2000
17. Ildiko RD, Heimesaat MM, Bushrab FN et al. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 48(12), 4848-4854 (2004
18. Shubar HM, Lachenmaier S, Heimesaat MM et al. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers. J. Drug Target. 19(2), 114-124 (2011
19. Shubar HM, Dunay IR, Lachenmaier S et al. The role of apolipoprotein E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis. J. Drug Target. 17, 257-267 (2009
20. Rabinow BE. Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785-796 (2004
21. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv. Drug Deliv. Rev. 59, 631-644 (2007
22. Liversidge EM, Liversidge GG. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv. Drug Deliv. Rev. 63, 427-440 (2011
23. US Pharmacopoeia Commission. Organic volatile impurities. In: The Official Compendia of Standards: The United States Pharmacopeia. US Pharmacopoeia Convention Inc., MD, USA (2007
24. Peters W, Robinson BL. Malaria. In: Handbook of Animal Models of Infection. Zak O, Sande M (Eds). Academic Press, London, UK, 757-773 (1999
25. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug discovery: Efficacy models for compound screening. Nat. Rev. Drug Discov. 3, 509-520 (2004
26. Osdene TS, Russell PB, Rane L. 2, 4, 7-Triamino-6-orthosubstituted arylpteridines. A new series of potent antimalarial agents. J. Med. Chem. 10, 431-436 (1967
27. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug. Del. Rev. 47, 3-19 (2001
28. Cauchetier E, Fessi H, Boulard Y, Deniau M, Astier A, Paul M. Preparation and physicochemical characterization of atovaquone-containing liposomes. Drug Dev. Res. 47, 155-161 (1999
29. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Impurities: Guideline for Residual Solvents, Q3C(R4). The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Geneva, Switzerland (2009
30. Lindfors L, Skantze P, Urban Skantze U, Rasmusson M, Zackrisson A, Olsson U. Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening. Langmuir 22, 906-910 (2006
31. Teeranachaideekul V, Junyaprasert VB, Souto EB, Muller RH. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology. Int. J. Pharm. 354, 227-234 (2008
32. Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 125, 309-313 (1995
33. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 125, 91-97 (1995
34. Puri V, Dantuluri AK, Kumar M, Bansal AK. Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Eur. J. Pharm. Sci. 40, 84-93 (2010
35. Park HJ, Kim MS, Lee SB, Kim JS, Woo JS. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process. Int. J. Pharm. 328, 152-160 (2007
36. Nokhodchi N, Bolourtchian NR. Crystal modification of phenytoin using different solvents and crystallization conditions. Int. J. Pharm. 250, 85-97 (2003
37. Hecq J, Deleers M, Fanara D, Amighi K. Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine. Int. J. Pharm. 299, 167-177 (2005
38. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 62, 3-16 (2006
39. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J. Pharm. Pharmacol. 56, 827-840 (2004